Francesco Marincola is the Chief Scientific Officer and Global head of Research at Translational and Advanced Medicine (TAM) Global, Nashville, TN. Most recently, he served as Chief Scientific Officer at Sonata Therapeutics, Boston MA and before he was Senior Vice President and Global Head of Research at Kite Pharma, where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre. Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI) as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief of the Infectious Disease and Immunogenetics section at the NIH Clinical Center. Francesco is the former President of the Society for Immunotherapy of Cancer (SITC). He is the founding Editor and Editor-in-Chief of the Journal of Translational Medicine (2003), and is the author of more than 700 peer-reviewed publications. Francesco received his M.D. from the University of Milan, Italy and completed his residency at Stanford University, California, USA. Francesco is also a fiction writer and a publisher, his work can be visited at: https://authorfrancomarincola.wordpress.com/